Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy

Published:2024-07-04 Issue:1 Volume:16 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

McCue Amelia C.¹,Demarest Stephen J.²,Froning Karen J.²,Hickey Michael J.²,Antonysamy Stephen²,Kuhlman Brian¹³^ORCID

Affiliation:

1. Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, USA

2. Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USA

3. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA

Funder

National Institutes of Health

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2024.2373325

Reference43 articles.

1. T cell-engaging therapies — BiTEs and beyond

2. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics

3. Perspective: Designing T-Cell Engagers With Better Therapeutic Windows

4. A guide to cancer immunotherapy: from T cell basic science to clinical practice

5. Full FDA Approval for Blinatumomab for ALL - NCI [Internet]. [cited 2023 Oct 2]. https://www.cancer.gov/news-events/cancer-currents-blog/2017/blinatumomab-all-fda-full-approval.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP